These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 1488869)
61. An unusually long survival without stem cell transplantation after the blast crisis phase of chronic myeloid leukemia: a case report. Choi Y; Yang Y; Beom SH; Park S Leuk Res; 2012 Jan; 36(1):e25-6. PubMed ID: 21996559 [No Abstract] [Full Text] [Related]
62. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Kantarjian HM; Talpaz M; Keating MJ; Estey EH; O'Brien S; Beran M; McCredie KB; Gutterman J; Freireich EJ Cancer; 1991 Sep; 68(6):1201-7. PubMed ID: 1873771 [TBL] [Abstract][Full Text] [Related]
63. [Recombinant alpha-interferon (reaferon) in the treatment of patients with chronic myeloleukemia]. Khoroshko ND; Savchenko VG; Kholopova EI; Kotel'nikov VM; Zakharova AV; Semenova EA; Marchenko VI Ter Arkh; 1990; 62(7):41-7. PubMed ID: 2251664 [TBL] [Abstract][Full Text] [Related]
64. Successful HLA-identical unrelated allogeneic bone marrow transplantation with a very low dose of stem cells for a patient with chronic myeloid leukemia in blast crisis. Arai H; Arai Y; Haraguchi K; Nakamura Y; Tsurumi S; Maki K; Aoyagi A; Nakamura Y; Saito K; Mitani K Leuk Lymphoma; 2002 Oct; 43(10):2067-9. PubMed ID: 12481912 [No Abstract] [Full Text] [Related]
65. Biotherapy of chronic myelogenous leukemia with interferon. Ozer H Semin Oncol; 1988 Oct; 15(5 Suppl 5):14-20. PubMed ID: 2461592 [No Abstract] [Full Text] [Related]
66. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea. Jehn U; Heinemann V Cancer Detect Prev; 1998; 22(3):258-64. PubMed ID: 9618049 [TBL] [Abstract][Full Text] [Related]
67. Autologous blood stem cell transplantation followed by recombinant alpha interferon as treatment for patients with high-risk chronic myelogenous leukemia. A report of 32 cases. Reiffers J; Montastruc M; Marit G; Cony-Makhoul P; Faberes C; Bilhou-Nabera C; Gharbi MJ; Bernard P; Vezon G; Broustet A Leuk Lymphoma; 1993; 11 Suppl 1():297-9. PubMed ID: 8251911 [TBL] [Abstract][Full Text] [Related]
68. Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge. Nand S; Barton K Leuk Lymphoma; 2007 Feb; 48(2):215-6. PubMed ID: 17325875 [No Abstract] [Full Text] [Related]
69. Granulocytic sarcoma presented as a reactivation of chronic myeloid leukemia after allogenic marrow transplantation. de Oliveira JS; Chauffaille Mde L; Colleoni GW; Morelli VM; Hauache OM; Alberti VN; Kerbauy J Sao Paulo Med J; 1998; 116(2):1689-91. PubMed ID: 9778890 [TBL] [Abstract][Full Text] [Related]
71. Aggregates of pseudo-Gaucher cells after treatment of chronic myeloid leukemia in blastic phase. Helbig G; Janikowska A; Kyrcz-Krzemien S Int J Hematol; 2015 Jan; 101(1):3-4. PubMed ID: 25380681 [No Abstract] [Full Text] [Related]
72. Acute lymphocytic blast crisis as an ocular manifestation of chronic granulocytic leukemia. Lakosha H; Simpson R; Patterson B; Minden M; Payne D; Lipton JH Can J Ophthalmol; 2000 Oct; 35(6):336-9. PubMed ID: 11091917 [No Abstract] [Full Text] [Related]
73. Successful treatment with chemotherapy and subsequent allogeneic bone marrow transplantation for myeloid blastic crisis of chronic myelogenous leukemia following advanced Hodgkin's disease. Punt CJ; Rozenberg-Arska M; Verdonck LF Cancer; 1987 Sep; 60(5):934-5. PubMed ID: 3300952 [TBL] [Abstract][Full Text] [Related]
74. Two consecutive spontaneous regressions to chronic phase in a patient with blastic transformation of chronic myelogenous leukemia. Cağirgan S; Sencan M; Tombuloglu M; Ozdemir E; Hekimgil M; Büyükkeçeci F Leuk Lymphoma; 1998 Apr; 29(3-4):423-5. PubMed ID: 9684940 [TBL] [Abstract][Full Text] [Related]
75. Occurrence of Donor Cell-derived Lymphoid Blast Crisis 24 Years Following Related Bone Marrow Transplantation for Chronic Myeloid Leukemia. Kurosawa S; Doki N; Hino Y; Sakaguchi M; Fukushima K; Shingai N; Hattori K; Watanabe K; Hagino T; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K Intern Med; 2016; 55(4):395-7. PubMed ID: 26875966 [TBL] [Abstract][Full Text] [Related]